National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011

BACKGROUND: Spironolactone, the only aldosterone antagonist available in China, improves outcomes in acute myocardial infarction (AMI) among patients with systolic dysfunction and either diabetes or heart failure (HF). However, national practice patterns in the use of spironolactone in China are unk...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Am Heart Assoc
Glavni autori: Guan, Wenchi, Murugiah, Karthik, Downing, Nicholas, Li, Jing, Wang, Qing, Ross, Joseph S, Desai, Nihar R, Masoudi, Frederick A, Spertus, John A, Li, Xi, Krumholz, Harlan M, Jiang, Lixin
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Ltd 2015
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599529/
https://ncbi.nlm.nih.gov/pubmed/26071031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.114.001718
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items